You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Private Equity >
Private Equity >
Water Desalination Plants
Demetra participates in a consortium with
Logicom Public Ltd
and Israeli company Mekorot Development and Enterprise Ltd. The consortium won two tenders issued by the Government of Cyprus, for two separate Desalination Projects in Cyprus. These include the Design, Build, Operation and Maintenance of a desalination plant in the Limassol district and the Renovation and Operation of an existing desalination plant in Larnaca.
The Limassol Desalination Plant, a 20-year Build Operate Transfer (BOT) project for the Government of Cyprus, is a €55M investment. It has an initial production of 40,000m³ per day, with infrastructure in place to increase production to 60,000m³ per day in the future. The modern, state-of-the-art plant was constructed in the Episkopi area of Limassol, and is the largest of its kind in Cyprus. Its official inauguration was held at the end of 2013, in the presence of the President of Cyprus as well as other highly esteemed guests. The plant is now fully operational, having effectively passed all its delivery tests, and is set to secure the potable water supply requirements for the Limassol district for the foreseeable future.
The Larnaca plant is a 25-year BOT project for the Government of Cyprus, and a €24M investment. The scope of the project involved the renovation and upgrading of an existing desalination plant, which in full operation produces 60,000m³ per day of drinking water.
Together, the two desalination plants will provide drinking water to almost half a million people, ensuring that there is no shortage of water as previously experienced in Cyprus.
Demetra holds a 20% stake in the consortium, which constitutes Demetra as the 3rd largest shareholder.
NIPD Genetics Ltd
NIPD Genetics LTD
is a privately held start-up company aiming to design, develop and manufacture non-invasive in vitro diagnostic tests for the diagnosis of genetic diseases and syndromes during the early stages of pregnancy. The company was founded in October 2010 as a spinoff from The Cyprus Institute of Neurology and Genetics. The vision at NIPD Genetics is to revolutionize prenatal diagnosis by developing and providing safe, simple, accurate and effective non-invasive tests for the early diagnosis of genetic disorders. NIPD Genetics has been successful in developing a NIPD test for the diagnosis of trisomy 21 during the early stages of pregnancy (as early as the 10th week of gestation). NIPD Genetics LTD has filed a patent application with the United States Patent and Trademark Office covering the identification of fetal-specific methylation markers on chromosomes 13, 18, 21, X and Y and the development of a Non-Invasive Prenatal Diagnostic (NIPD) test for Down syndrome (trisomy 21).
Demetra holds a 5.1% stake in NIPD Genetics, which constitutes Demetra as the 3rd largest shareholder.
© Demetra Investments Public LTD
Designed and Developed by Logicom Solutions 2015